A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma

Asao Hirose,Hideo Koh,Mika Nakamae,Yasuhiro Nakashima,Mitsutaka Nishimoto,Hiroshi Okamura,Yosuke Makuuchi,Masatomo Kuno,Teruhito Takakuwa,Kentaro Ido,Kazuki Sakatoku,Masayuki Hino,Hirohisa Nakamae

DOI: https://doi.org/10.1038/s41409-024-02231-4

2024-02-15

Bone Marrow Transplantation

Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATL), but outcomes are still unsatisfactory [1, 2]. The first choice of donors for allo-HCT of ATL are HLA-matched relatives, but sibling donors are difficult to find because ATL is common in elderly individuals [3]. The next candidate, an HLA-matched unrelated donor, takes time to coordinate and can be difficult to transplant at the appropriate time [4]. Therefore, cord blood (CB) is a candidate alternative donor source, but the 1-year OS was only 38% in Japan [5]. Recently, Tanaka et al. conducted a multicenter single-arm trial of HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide (PTCy-Haplo PBSCT) for aggressive ATL, which showed a good 2-year OS of 73% with a median follow-up of 572 days [6]. To our knowledge, only one study has compared HLA-haploidentical allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide (PTCy-Haplo HCT) with others, with a median follow-up of 728 days [7]. To date, there have been no reports on the long-term comparison of PTCy-Haplo HCT with transplantation using other donor types.

oncology,immunology,hematology,transplantation